Remus Pharmaceuticals results, half year to Mar 2026
NSE: REMUSPharmaceuticals & Biotechnology
Remus Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2023 · Issue price ₹1,229
Last close ₹873.80down ₹0.55 (0.06%)
Share price at the NSE close on 29 Oct 2026. Previous close ₹874.35.
29 Oct: open ₹856.20, high ₹881.05, low ₹855.00
52-week range of traded prices to 29 Oct 2026
₹580.00Low, 9 Mar 2026₹1,039.00High, 15 Oct 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results, dividend and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹1,030 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 27.84
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.93
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.06
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,60073.1% delivered
Remus Pharmaceuticals filed its results for the half year to Mar 2026 on 20 May 2026 at 8:01 pm, consolidated: the company and its subsidiaries together.
Results for the half year to Mar 2026
₹ crore.Remus Pharmaceuticals annual results and balance sheet
- RevenueRevenue from operations. Money earned from selling the company's goods and services in the period. Revenue from operations in the glossary
- ₹453 Cr+30.4% on a year ago · +13.3% on the half year beforeChange on a year ago. The change against the same half year a year before: (this half year's figure less that half year's) divided by that half year's, times 100. Left out where either figure is a loss, or across a change of basis named under the table, on the lines it affects.
- Operating profitOperating profit before depreciation (EBITDA). Revenue less operating expenses: what the business earns from its operations before depreciation, interest and tax. Operating profit before depreciation (EBITDA) in the glossary
- ₹30 Cr+21.5% on a year ago · +10.7% on the half year before
- Net profitNet profit. What is left of revenue and other income after every cost, interest and tax. Net profit in the glossary
- ₹25 Cr+19.5% on a year ago · +13.8% on the half year before
- Earnings per shareEarnings per share. Profit belonging to shareholders divided by the number of shares, restated for later splits and bonuses so they do not break the line. Earnings per share in the glossary
- ₹20.86+19.5% on a year ago · +13.8% on the half year before
- Operating marginOperating margin. Operating profit before depreciation as a percentage of revenue: how much of each rupee of sales is left after running costs. Operating margin in the glossary
- 6.6%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 5.4%
From revenue to net profit, ₹ crore
- Revenue453
- Materials and goods−393
- Employee costs−6.6
- Other expenses−24
- Operating profit30
- Depreciation−1.5
- Other income+3.8
- Finance costs−0.8
- Profit before tax31
- Tax−6.7
- Net profit25
Remus Pharmaceuticals results by half year
Consolidated: the company and its subsidiaries together. Latest half year to Mar 2026. Results for the half year to Sep 2026 are due by 14 Nov 2026, 45 days after it ends. Every company's dates are on the results calendar.Results filings and date
Revenue and net profit by half year, ₹ crore
- Revenue
- Net profit
Peak revenue ₹453 Cr, half year to Mar 2026; lowest ₹29 Cr, half year to Sep 2023
Operating and net margin by half year, per cent
- Operating margin
- Net margin
| ₹ crore | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025Filed 10 Nov | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue from operations | 29 | 183 | 273 | 348 | 400 | 453 |
| Operating expenses. What the business spent to run itself in the period, materials, staff and other costs, before depreciation, interest and tax. Operating expenses in the glossary | 20 | 165 | 252 | 323 | 373 | 424 |
| Materials and goods boughtCost of materials and goods. Raw materials used and goods bought for resale in the period, adjusted for the change in stock held. Cost of materials and goods in the glossary | 14 | 151 | 232 | 301 | 350 | 393 |
| Employee costsEmployee costs. Salaries, wages, bonuses and other benefits paid to staff in the period. Employee costs in the glossary | 3 | 4 | 6 | 7 | 6 | 7 |
| Other expensesOther expenses. Every operating cost besides materials and staff: power, rent, freight, repairs, marketing and the like. Other expenses in the glossary | 3 | 10 | 14 | 15 | 18 | 24 |
| Operating profit before depreciation | 9 | 19 | 21 | 25 | 27 | 30 |
| Operating margin | 31.9% | 10.1% | 7.5% | 7.1% | 6.7% | 6.6% |
| Depreciation and amortisationDepreciation and amortisation. The part of the cost of plant, buildings and other long-lived assets charged against each year they are used. Depreciation and amortisation in the glossary | 0 | 0 | 0 | 1 | 1 | 1 |
| Other incomeOther income. Income from outside the main business, such as interest on deposits, dividends received and gains on investments. Other income in the glossary | 2 | 4 | 3 | 3 | 3 | 4 |
| Finance costsFinance costs. Interest and the other costs of borrowing in the period. Finance costs in the glossary | 0 | 0 | 1 | 1 | 1 | 1 |
| One-off itemsExceptional items. Gains or losses the company reports separately because they are not expected to recur, such as selling a business or writing down an asset. Exceptional items in the glossary | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 10 | 21 | 22 | 25 | 28 | 31 |
| 3 | – | 3 | 5 | 6 | 7 | |
| Tax rateEffective tax rate. Tax charged as a percentage of profit before tax. Effective tax rate in the glossary | 25.0% | – | 15.6% | 18.9% | 22.6% | 21.4% |
| Share of profit of joint ventures and associatesShare of profit of joint ventures and associates. The group's share of the profit of companies it part-owns and does not consolidate, as stated. It is part of net profit but not of revenue or operating profit: their sales and costs are not in the group's lines. Share of profit of joint ventures and associates in the glossary | −2 | – | – | – | – | – |
| 6 | 16 | 14 | 21 | 22 | 25 | |
| Other comprehensive incomeOther comprehensive income. Gains and losses booked straight to net worth rather than through profit, such as changes in the value of some investments, pension plans and currency translation. Other comprehensive income in the glossary | – | – | – | 70 | 34 | 26 |
| Total comprehensive incomeTotal comprehensive income. Net profit plus other comprehensive income. Total comprehensive income in the glossary | – | – | – | 91 | 55 | 51 |
| Net margin | 19.4% | 8.7% | 5.1% | 5.9% | 5.4% | 5.4% |
| Net margin without joint ventures and associatesNet margin without joint ventures and associates. Net profit less the share of profit of joint ventures and associates, as a percentage of revenue: the margin on the businesses whose revenue the statement carries. Shown where the company states such a share. Net margin without joint ventures and associates in the glossary | 26.9% | – | – | – | – | – |
| Earnings per share | – | – | – | ₹17.46 | ₹18.33 | ₹20.86 |
Earnings per share in rupees, restated for later splits and bonuses.